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Response to Reviewer’s Critique: 
Reviewer #1
Comment:  The paper is hard to read.  It is the terminology/style used and also the 
content.  For example, on page 11 top paragraph they refer to the stress fibers being 
“remodeled” but one who is not an expert in stress fibers must look at the figure to 
understand what they mean.  Likewise in that same paragraph, they state that actin stress 
fiber remodeling was “much more restricted”.  This terminology is not easy for a general 
audience to understand.  Many of the paragraphs, such as the first one in the 
Introduction contain many different facts and long sentences with multiple points being 
made. 
Response:  We have re-written most of the manuscript to present concepts and data in a 
more straightforward and simplified manner.  In the text, we have replaced ambiguous 
descriptions or jargon  (e.g.“actin remodeling”, “much more restricted”) with what we 
hope is clearer language (e.g. “disassembly of actin stress fibers” and “reduced”).  We 
have also quantified the disassembly of actin stress fibers using image analysis to reduce 
ambiguity about the changes that Rhamm loss has on the actin cytoskeleton organization.  
 
Comment:  The authors comment on reduced clot formation (in the Abstract and Results 
on page 5) but do not indicate how it relates to their findings on cell migration.  Also they 
claim reduced clot formation and show it nicely in the supplemental figure but in figure 
1A clot formation looks increased in the KO cells.  A more representative figure should 
be shown if this was their general finding. Unless they have more quantitative 
information and a proposed mechanism relative to their findings in this paper, they may 
want to omit this information.  
Response:  We agree with Reviewer 1’s comments that the data on clot formation shown 
in the original manuscript were not well documented and were peripheral to the main 
focus of the manuscript on cell migration. We have omitted these data and descriptions in 
the revised manuscript.  
 
Comment:  Figure 1B.  The number on the panel should be 2.50 not 2.25. 
Response:  This graph has been removed and Figure 1 completely modified in deference 
to comments by several of the reviewers.   
 
Comment:  Figure 3B.  The Rh-/- in the upper and lower panel should be similar but they 
appear very differently. Some comment is needed.  
Response:  This point was a concern of all of the reviewers and was partly due to the 
inclusion of two types of ERK1,2 activators (PDGF and serum) in one figure. To address 
this, we have made the following modifications. Figure 3 now contains only the 
histochemical staining for active ERK1,2.  Figure 4 shows a more comprehensive in vitro 
analysis of ERK1,2 activation in fibroblasts responding to one type of stimulus (serum). 
In vitro data showing ERK1,2 activation in response to PDGF have been placed in a new 
Supplemental Figure (III).   
The reviewers concerns also brought up an important point about the semi-
quantitative nature of the western blot assays previously shown in Fig. 3B. We have 
therefore now included results of ELISA assays that quantify ERK1,2 activation in 
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cultured cells.   These data are presented as Figure 4A.  We have now used our western 
blot analyses to re-quantify ERK1 activation in Rh-/- and Rh-rescued fibroblasts (new 
Fig. 4B).  We performed new confocal analyses of ERK1,2 activation Rh-/- and Rh-
rescued fibroblasts in response to serum (instead of PDGF). We quantified ERK1,2 
activation in response to PDGF and this is now presented as a graph in Supplemental Fig.  
IIIb.   We believe that these changes now clearly and consistently show a similar pattern 
for aberrant ERK1,2 activation in Rh-/- vs. Rh-rescued (or Wt) fibroblasts.    
  
Comment:  Figure 5.  They should omit the diagrams.  The paper has so many bar graphs 
so they could put these data in a table.   
Response:  We agree with the reviewer that this figure should be simplified.  However, 
we feel strongly that the timelapsed images of the wounds provide data that is difficult to 
convey as a table.  We have therefore removed Figure 5A (depicting wildtype and 
Rhamm-/- fibroblasts) and now include migration of Rh-/- and Rh-rescued fibroblasts in 
wound gap migration assays as well as collagen gel assays.  Data showing the migration 
and invasion of primary Wt and Rh-/- fibroblasts have been moved to a new 
Supplemental Figure IV (a,b).   
 
Comment:  Figure 6 would greatly benefit from photos of the cells for the elongation and 
roundness claims.  Invasion is usually associated with protease activity.  Has protease 
activity been examined?  
Response:  Reviewer 3 also asked for clarification of this Figure. We have deleted Figure 
6B since Reviewer 3 did not find the assay compelling, and as noted above included the 
collagen gel assay in Figure 5.  We agree that assessing protease activity is an interesting 
avenue to pursue. However, given the complexity of this field, we feel that inclusion of 
such data is beyond the scope of the present manuscript. 
 
Comment:  Figure 7.  Is HA in serum? Some comment is needed.  
Response:  The reviewer is of course correct.  Hyaluronan is present in serum at a 
concentration of  <10 pg/L. In our experience, this concentration is not sufficient to 
stimulate cell motility nor, to our knowledge, has this concentration of HA been reported 
to promote motility.   We therefore consider it unlikely that serum HA contributes to the 
motility response to fetal calf serum.  For quantifying the effect of HA, Fibroblast 
cultures were serum-starved prior to exposure to exogenous HA.    
 
Comment:  Figure 8A.  The symbols need to be larger as this figure is hard to read.  Part 
B would make a better table.  
Response:  Figure 8 has been revised to accommodate the other reviewers’ comments.  
We have also made the graphs of ERK1,2 activity larger for clarity.  
  
Comment:  In the Methods section, they should indicate how many times each experiment 
was done and the number of replicates.   This is especially important for the wound 
healing in vivo. 
Response:  We have now included this information both in the Methods section.  
 
 
 3
Reviewer #2
Comment 1a:  While the authors have used a lot of statistical analysis to show the defects 
in wound healing in the KO animals, the pictures are not of high quality.  It is difficult to 
interpret what is being stated, and it seems rather subjective.  
Response:  This is also a concern of other reviewers.  We have therefore replaced the 
images shown in Figure 1B as a new Figure 1A.  This shows a collage of sections of the 
wound site that has been stained for tenascin so that granulation tissue can be easily 
observed. We have quantified the area of tenascin positive granulation tissue in Wt and 
Rh-/- wounds and present these data as Figure 1B.  We repeated this experimental series 
using sections 2 and 6 of serial sections starting at the wound center to ensure that the 
same wound position was used for both Wt and Rhamm-/- samples.  We have omitted the 
data the reviewer is concerned about (previous Figure 1B and 2A). 
For example the higher magnification image of the Rh-/- mice in fig 2B (should be Figure 
1B?) seems to be of the lower part of the skin, where the fat pad is (as we can see a lot of 
vacuoles). 
Response:  Rhamm-/- wounds aberrantly accumulate adipocytes within granulation tissue 
accounting for the large number of vacuolated cells depicted in the previous Figure 1B.  
We have retained this micrograph, as it is representative of the appearance of Rhamm-/- 
granulation tissue (now Figure 2A) but have provided additional data showing that 
Rhamm-/- granulation tissue contains adipocytes (new Figure 2C).    
 
The authors state that the fibroblasts are less dense in the KO compared to the WT, but 
this is not reflected in the pictures shown, in fact, there are areas in the WT shaded area 
of the wound that look less dense (on the left hand side of the wound). 
Response:  We agree with the reviewer that Rhamm-/- wounds exhibit areas of high 
fibroblast density as well as areas of lower fibroblast density, and this micrograph (now 
Figure 2A) is representative of this heterogeneity.  The quantification of fibroblast 
density (now Figure 2A) is based on number of fibroblasts per granulation tissue area in 
each field of view and therefore represents an average value (N= 4 sections from 8 
animals for each genotype now described in the new Figure 2 legend).  However, we did 
not note the heterogeneity in the previous manuscript and thank the reviewer for making 
this point.  We have now included this in the new manuscript in the Figure 2 legend. 
 
Comment 1b:  The authors should show the resolution of the actual wound on the back of 
the animals, at different times to give a better picture of how these wounds heal. 
Response:  We have repeated the wounding experiments and have taken photographs of 
wound sites on the animal’s backs from day 0 to day 7.  These photographs shown as 
Supplemental Figure Ib and the wound area quantified from these experiments are 
presented in a lower panel of this Figure.    
The pictures that are presented in figure 2 and supplementary fig1 do not convincingly 
represent the defects that have been described in the text.  
Response:  As noted above, we have repeated the wounding experiments and stained 
granulation tissue with tenascin.  Using this method, we are confident that the data now 
presented as Figure 1A,B and Supplemental Figure Ia are representative of, and 
accurately quantify the defective wound repair of Rhamm-/- mice that we describe in this 
manuscript.   
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Comment 1c:  The authors should use overlapping pictures to show the extent of the 
wound. The use of a molecular marker, like αv or ß6 integrin to delineate wound edge 
would also be helpful.  
Response: As requested, we have presented wound sites as overlapping pictures (Figure 
1A).  We have replaced data quantifying granulation tissue formation/resolution from 
previous images with data using tenascin-positive areas to quantify granulation tissue 
formation/resolution (Figure 1A).  We originally used Masson’s trichrome staining to 
detect wound bed edges for quantifying wound contraction (now Supplemental Figure 
Ic).  These wound contraction data supplement those shown in the wound photographs 
(Supplemental Figure Ib) and are now presented as Supplemental Figure Ic.  
 
 Comment 1d:  What is the brown staining that is seen in the sections in figure 1? 
Response:  Sections were stained for vimentin.  Only the higher magnification 
micrographs have been retained in the present manuscript.  
 
Comment 2a:  In figure 3 the section of wounded 3d Rh-/- animal again have a lot of 
vacuoles in them.  
Response:  As noted above, these are adipocytes, which accumulate to a greater extent in 
Rh-/-  vs. Wt wound sites. 
 The 7d KO wound looks very washed out, and there seem to be fewer nuclei, which is at 
odds with the data that Rh-/- wounds have more cells per field compared to WT wounds 
both at 3d and 7d wounds.  
Response:  Panel day 7 Rh-/- in Figure 3 has been replaced with an image where cell 
nuclei were more clearly counter stained. The fibroblast density in day 7 Rh-/- wounds 
(Figure 3) is lower than WT and this is consistent with both the previous and new 
micrograph of day 7 Rh-/- granulation tissue.    
 
Comment 2b:  What is the correlation between the low levels of ERK expression and the 
miscuing of granulation tissue formation?  
Response:  Both Wt and Rh-/- granulation tissue fibroblasts in vivo (“unpublished data”) 
and Rh-/- and RhFL-rescued fibroblasts in vitro express similar levels of ERK1,2 protein 
(Figure 4A,B).  Activation of ERK1,2 is less sustained in Rh-/- fibroblasts.  This low 
level of activation is associated in vivo with sparse fibroblast density and abnormal 
differentiation, and with reduced migration in vitro.  This correlation is predicted by 
published reports noting an effect of ERK1,2 on migration, adipogenesis and 
myofibroblast differentiation.  This relationship is noted on page 12 of the Discussion 
section in the revised manuscript.    
 
Comment 3:  In figure 4 the confocal data looking at the activation of phospho-ERK after 
PDGF stimulation does not correlate with the western blot analysis in figure 3B. 
According to the blots, the Rh-/- cells show sustained activation for 30’ after stimulation, 
and only then does it drop off. How do the authors reconcile this discrepancy?  
Response:  We agree with the reviewer that the confocal images did not reflect the 
western blot data shown in the previous Figure 3B.  As per our comments to Reviewer 1, 
we have repeated all of the ERK1,2 activation data in Rh-/- and Wt or RhFL-rescued 
fibroblasts and these are now presented as Figure 4.  We have concentrated on presenting 
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activation of these MAP kinases in response to serum to improve data clarity and deleted 
or moved data showing responses to PDGF-BB to the supplemental figures.  We have 
deleted confocal images in the previous Figure 4 (which showed ERK1,2 activation in 
response to PDGF-BB) and replaced these with a panel of confocal micrographs showing 
ERK1,2 activation in response to serum (Figure 4C).   
 
Comment 4:  With the scratch wound assays (figure 5), it is not clear to this reviewer, 
what the red and black squiggly lines represent. It would be simpler to show images from 
the time-lapse movies that the authors have done to show the defective migration.   
Response:  The lines represent the migration trajectories of individual cells.  We feel that 
this provides important information discussed in the Results section (pages 8 and 9) that 
is difficult for readers to distill from either static or timelapsed images.   
Also it does not seem surprising that the Rh-/- cells have a migration defect, given that it 
has been shown by these authors that “HA:Rhamm interactions promote cell locomotion 
via a protein tyrosine kinase signal transduction pathway that targets focal adhesions” 
and that “tyrosine kinase pp60c-src is associated with Rhamm in cells and is required for 
Rhamm mediated cell motility” (Hall and Turley 1995). 
Response:  We agree that our results showing an effect of Rhamm loss on cell migration 
is predicted by previous data from cultured cells.  However, in vitro analyses often do not 
predict in vivo functions and our previous studies also did not address whether other 
genes (e.g. CD44) can compensate for Rhamm in regulating migration and whether 
Rhamm-regulated migration is involved in a physiological process.  We had expected 
CD44 to compensate for Rhamm loss since we have previously published that these 
receptors have overlapping functions and that Rhamm can compensate for CD44 to 
mediate migration and invasion during disease processes such as arthritis (Nedvetski et 
al., 2004, Proc. Natl. Acad. Sci. U.S.A.101:18081).   Our results suggesting that Rhamm 
is involved in regulating fibroblast migration during the physiological process of wound 
repair is therefore noteworthy.  These points of view are now emphasized in the 
Discussion section (page 13).   
There is no attempt to address the mechanism for changes in cell migration. What is the 
correlation between Rhamm and MAP Kinase signaling? We apologize for this omission.  
Response:  Our results in the present manuscript showing an effect of Rhamm on MAP 
kinase signaling are consistent with our and other’s previous data providing evidence that 
Rhamm can act at the level of receptor protein tyrosine kinases to activate upstream 
effectors of ERK1,2 including src, and Ras.  We have now included these important 
points in the Discussion section of the revised manuscript (page 12).     
 
 
Comment 5:  The authors’ state in the text on page 9 that migration defect was displayed 
by primary dermal and “other” cells. What are the other “type of fibroblasts” that show 
the migration defect?  
Response:  In this study, we used primary embryonic fibroblasts (MEF), immortalized 
embryonic fibroblasts (which were also transfected with full length Rhamm and/or 
mutant active Mek1), and primary dermal fibroblasts from littermatched Wt and Rh-/- 
mice.  We apologize for the poor documentation of this in the previous manuscript.  We 
have attempted to make the origin of the fibroblasts used for each experiment more clear 
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by presenting the data using immortalized Rh-/- and RhFL-rescued fibroblasts in text 
Figures while retaining the data using primary Wt and Rh-/- MEF in the Supplemental 
Figures.    
 
Comment:  The fact the rescue of Rh-/- phenotype was done using immortalized cells was 
only indicated in the figure legends and not in the text. It is not clear if these rescued 
cells are being compared to primary cells from the KO mice or with transformed KO 
cells in the migration assays.  
Response:  We compared only primary Wt with primary KO fibroblasts and immortalized 
KO with RhFL-rescued KO fibroblasts.  We have clarified this and apologize for the lack 
of labeling.   
 
Comment:  Why was the rescue not done using the primary cells?   
Response:  The transfection efficiency of primary fibroblasts is very low (<10%) and 
precluded their use in many analyses presented in this manuscript.  We deliberately 
isolated immortalized Rh-/- and RhFL-rescued fibroblast lines to circumvent this difficulty 
since these are much more easily transfect (transfection efficiency with lipofectamine 
Plus is 60-70%).    
 
Comment:  Do the transformed KO and rescued cells have the same response in the 
migration and invasion assays as the primary WT and KO cells?  
Response:  The cell lines we used are not transformed but rather immortalized (they do 
not grow in soft agar or form foci in focus forming assays that would indicate 
transformation).  Both cell lines exhibit similar phenotypes although the rates of 
migration, for example, differ slightly.  We have separated these data as noted above to 
prevent reader confusion.     
 
Comment:  If not these two cell types should not be compared.  
Response:  We agree it would never be appropriate to compare primary to immortalized 
lines.   
Minor Comment:  It would be good to see a picture of non-wounded WT and KO skin for 
comparison.   
Response:  We agree that this is informative and have now included micrographs of 
uninjured skin as a new Supplemental Figure IIa.    
 
Reviewer #3 
Comment 1:  P. 7 and Discussion p. 13: Neither proliferation nor apoptosis in 
granulation tissue of Rh-/- mice was significantly different then Wt granulation tissue 
despite difference in ERK 1, 2 expression (Figure 3A). The author point out (p 13) that 
they previously reported that “Rhamm regulates cell proliferation in both fibroblasts and 
fibromatosis cell under conditions of low density, but not high density.” As presented, 
this sounds like a correction. If it is not a correction, then additional comments should be 
made to explain or justify the differences in results. 
Response:   This comment was not meant as a correction of previous results and we thank 
the reviewer for pointing this out.  We have modified the discussion to include possible 
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reasons for the discrepancy in our present results obtained in vivo vs. these previous 
results that were obtained in vitro (Discussion, second paragraph, page 11).   
For example, does Rhamm have effects on expression of p27 that regulates both 
migration and proliferation.   
Response:  This is a very interesting suggestion that we will certainly consider for future 
experiments.  However, we feel that this is beyond the scope of the present manuscript.   
 
Comment 2:  Figure 1 B and Supplement Figure 1, Figure 2A. These figures are 
inadequate to explain how the areas of the granulation tissue were established. This is 
particularly true since the area of the granulation tissue differs at the center and edge of 
the wound. The data as presented does not make it clear how the authors arrived at their 
numbers. Do markers of dermal remodeling (thrombospondin, Tenascin) help in 
identifying the granulation tissue for the reader?  
 
Response:  We agree with the reviewer.  We have redone the wounding experiments and 
have restricted our analyses to the wound center, which is most easily identified.  We also 
matched age (18 months), gender (male) and wound placement (left flank) to facilitate 
data interpretation. We also thank the reviewer for the excellent suggestion to use 
tenascin as a marker for granulation tissue.  We have now used tenascin-staining to 
measure granulation tissue boundaries in Wt and Rh-/- wounds.  These new data are 
presented in a new Figure 1A,B.     
 
Comment:  Do differences in migration of the fibroblasts that are described in the rest of 
the manuscript account for the differences in granulation tissue?  
Response:  This is an important point that we have addressed indirectly in this manuscript 
in the sense that we did not observe differences in either proliferation or apoptosis in vivo 
leaving migration as a reasonable alternative.  Defective migration is consistent with our 
in vitro data and with the differences in ERK1,2 activity observed both in vivo and in 
vitro.  We are currently using knock-in approaches and ex vivo image analysis to directly 
address this point.    
 
Comment:  Where does Rhamm localize in the granulation tissue of the WT?   
Response:  We (Savani et al., 1995 Proc West Pharmacol Soc 38:131), and others 
(Lovoorn et al., 1998, J Pediatr Surg 33:1062), have previously published that Rhamm is 
expressed in granulation tissue fibroblasts as well as in white cells present in granulation 
tissue.   
 
Comment:  Figure 3. It is not clear from Figure 3A that ERK1,2 expression is different in 
the Wt and Rh-/- tissue.  
Response:  The figure shows ERK1,2 activity and not total ERK1,2 expression.  
Quantification of phospho-ERK1,2 was done using image analysis of 15 separate areas in 
3 serial tissue sections/mouse used for the experiments.  The values indicate significant 
differences in phospho-ERK1,2 activity although no detectable differences in ERK1,2 
protein expression were detected in parallel sections stained for total ERK1,2 protein 
(data not shown).   We have attempted to clarify this in the Figure legend (Figure 3 in 
revised manuscript).  
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Comment:  What happened to panel Day 7 Rh-/-, it looks bleached out?  
Response:  We thank the reviewer for noting this.  This panel has been replaced with one 
where the counter staining for the nucleus was similar to that of the other images in the 
panel (now Figure 3). 
 
Comment:  Figure 3B, published studies have shown that adhesion via integrins activates 
ERK. Does the contribution of Rhamm to ERK activation require adhesion via integrins?  
Response:  We agree with the reviewer that this is an interesting and appropriate question 
given our data showing a role for Rhamm in focal adhesion turnover and FAK de-
phosphorylation.  Therefore part of our future research focus is directed towards 
identifying the pools of ERK1 that are affected by Rhamm including those in focal 
adhesions.  However, this is a complex field and we feel is beyond the scope of the 
present manuscript.   
 
Comment:  Do differences in concentration of PDGF-BB compensate for the reported 
differences in ratios of P-ERK/total ERK (Figure 3B). This would suggest that Rhamm 
may increase the relative concentration of PDGF.   
Response:  This is again an interesting question but complicated to address using PDGF-
BB as a stimulus. The highest PDGF-BB concentration we used was 50ng/ml and the 
lowest concentration was 2.5ng/ml. 25-50ng/ml of PDGF-BB are typically motogenic for 
fibroblasts while smaller concentrations are mitogenic.  We have attempted to address the 
reviewers question using concentrations of PDGF-BB that vary between 20-50ng/ml.  We 
did not observe significant differences in stimulation but feel that other stimuli might be 
more appropriately used for these experiments.  Since this will require further in depth 
analyses, we have not included these data in the present manuscript but thank the 
reviewer for this excellent suggestion.    
 
Comment:  Figure 6B. Reporting the invasion of the fibroblasts as “Elongation” or 
“Roundness” factors is not adequate. Did the cells invade or not and how far?  
Response:  We agree with the reviewer’s opinion of using “roundness” as a measure of 
invasion and have deleted this from the manuscript.  We have retained the collagen gel 
analysis where we measure the number of fibroblasts that migrate into the central “plug” 
containing collagen/PDGF-BB/HA (new Figure 5B).  
 
Comment:  Figure 7C. The reported differences in FAs are not apparent from the panels 
present.   
Response:  We agree and have removed these data from the manuscript.  We have 
retained the microgaphs showing differences in Rh-/- vs. RhFL-rescued actin stress fibers, 
and have quantified this difference (new Figure 7) to provide evidence that Rhamm is 
required for disassembly of the actin cytoskeleton.   
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ABSTRACT 
Rhamm is a hyaluronan (HA) binding protein with limited expression in normal tissues and high 
expression in advanced cancers. Here we have identified a physiological function for Rhamm 
during excisional skin wound repair. Genetic deletion of Rhamm impairs wound contraction and 
granulation tissue formation/resolution.  This is associated with enhanced inflammation, sparse 
fibroplasia and aberrant differentiation as indicated by reduced myofibroblast conversion and 
increased adipocyte accumulation. Sparse fibroplasia is associated with an inability of Rhamm-/- 
(Rh-/-) fibroblasts to resurface large (>3mm) scratch wounds or invade HA-supplemented ECM 
gels to the extent of wild-type or Rhamm-rescued fibroblasts.  These effects result from altered 
activation kinetics and subcellular targeting of ERK1,2 since stable introduction of constitutively 
active Mek1 rescues these defects in Rh-/- fibroblasts. Our results identify Rhamm as a 
fibrogenic factor required for appropriate cueing of migration/differentiation necessary for 
repair, and as an essential regulator of ERK1,2 motogenic-signaling pathways required for 
wound repair.      
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INTRODUCTION 
Rhamm is a HA-binding protein that is either not expressed or expressed at low levels in 
normal adult tissues but is highly expressed in aggressive human tumors (Adamia et al., 2005; 
Tammi et al., 2002; Toole, 2004).  Analyses of animal models have confirmed instructive roles 
for Rhamm in tumorigenesis and in other disease processes such as arthritis.  Roles for Rhamm 
in these diseases are consistent with its well-documented in vitro functions in migration and 
proliferation/apoptosis (Turley et al., 2002).  Since migration and proliferation/apoptosis are 
essential functions for morphogenesis and tissue homeostasis, it is surprising that genetic 
deletion of Rhamm does not affect embryogenesis or adult homeostasis.   Indeed, to date, a 
physiological function for Rhamm has remained elusive.   
Rhamm was originally isolated from subconfluent migrating fibroblasts (Turley, 1982) 
and subsequently cloned from mesenchymal progenitor cells (Hardwick et al., 1992).  Antibodies 
prepared against a shed form of Rhamm block HA-stimulated-fibroblast motility, suggesting that 
Rhamm is a cell surface protein that transduces motogenic signaling pathways in culture (Turley 
et al., 2002).  Rhamm-bound HA is detected in cancer cell lines (Adamia et al., 2005) and shown 
to exist also in intracellular compartments/structures including the actin and microtubule 
cytoskeletons, nucleus and cytoplasm (Adamia et al., 2005). These results suggest that Rhamm 
has extracellular and intracellular functions.  However, whether or not Rhamm acts as a cell 
surface receptor for HA became controversial partly because cloning of the human (Crainie et 
al., 1999; Hofmann et al., 1998; Wang et al., 1996) and mouse genes (Hofmann et al., 1998) 
revealed an absence of both a signal peptide required for export through the golgi/ER and 
membrane spanning domain(s) common to most cell surface receptors.  In this and other 
characteristics, Rhamm resembles a group of intracellular proteins (e.g. epimorphin/syntaxin-2, 
autocrine motility factor/phosphoglucose isomerase) that also lack these signature characteristics 
of cell membrane receptors but which are nevertheless found at the cell surface and transmit 
signals across the cell membrane to regulate a number of cellular functions (Radisky et al., 
2003).  
We have shown that Rhamm expression is high in aggressive fibromatoses (desmoid) 
tumors (Tolg et al., 2003).  We further demonstrated that genetic deletion of Rhamm strongly 
reduced desmoid tumor initiation and invasion in a mutant APC and β-catenin-driven mouse 
model of this mesenchymal tumor.  Fibroproliferative processes such as aggressive fibromatosis 
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resemble proliferative/migratory stages of wound healing (Cheon et al., 2002).  The expression 
of Rhamm is modulated during wounding (Lovoorn et al., 1998) and by fibrogenic cytokines 
such as TGF-β (Samuel et al., 1993).  Since factors that regulate fibroblast function play dual 
roles in wound repair and tumorigenesis (Bissell, 2001; Park et al., 2000), we have assessed in 
the current study whether Rhamm is involved in repair of excisional skin wounds using Rh-/- 
mice.  The results show that Rhamm loss results in defects in early phases of skin repair, in 
particular in granulation tissue formation and resolution. This defect is associated with impaired 
migration/motility of fibroblasts and is due to aberrant kinetics of ERK1,2 activation/subcellular 
targeting. 
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RESULTS 
Rhamm expression is required for granulation tissue formation and resolution in skin wounds. 
Rhamm expression increases during repair of excisional wounds on human skin 
xenografts in immune compromised mice (Lovvorn et al., 1998) and following scratch wound of 
smooth muscle cell monolayers in culture (Savani et al., 1995).  In the present study, Rhamm 
expression was followed during the first 7 days after excisional wounding of mouse skin.  RT-
PCR analysis of wounds showed that Rhamm expression was low in uninjured skin (Suppl. Fig. 
Ia).  A marked increase in Rhamm mRNA was obvious one day after injury and expression was 
increased until day 3 when mRNA levels began to drop.  By day 7 Rhamm mRNA levels were 
only slightly higher than those observed in uninjured skin.  These results indicate that Rhamm is 
expressed during the early stages of excisional skin wound repair, which include wound 
contraction, re-epithelialization and granulation tissue formation.  We therefore next assessed the 
consequences of Rhamm loss to the integrity of these early processes by photographing wound 
sites and by analyzing serial cross sections cut through wound centers.     
  Wt and Rh-/- wounds both contracted by day 1-3 after injury, but contraction of day 3 
Rh-/- wounds was significantly reduced compared to Wt wounds (Suppl. Fig. Ib).  Differences in 
wound contraction were not detected at later times when wound areas were measured from 
photographs (Suppl. Fig. Ib).  By day 14, Wt and Rh-/- wound sites both appeared resolved at the 
macroscopic level ("unpublished data").  However, when the distance between wound edges was 
measured using tissue sections cut through wound centers, significant reductions in the 
contraction of Rh-/- wounds could be detected at days 1 and 3 but also at day 13  (Suppl. Fig. Ic). 
Since granulation tissue myofibroblasts contribute to wound contraction, since loss of Rhamm 
results in a significant decrease in the thickness of the dermis before injury and since resolution 
of Rh-/- dermis was delayed, as indicated by continued fibroplasia and reduced differentiation of 
dermal structures (day 21, Suppl. Fig. IIa,b), we next focused upon the consequences of Rhamm 
loss on granulation tissue formation/resolution.   
A temporal spatial defect in the formation and resolution of granulation tissue was 
observed in Rh-/- vs. Wt wounds (Fig. 1A, B).  Tenascin-positive granulation tissue was 
abundant in day 3 Wt wounds and began to decrease by day 7 (Fig. 1A).  At day 14, wound 
granulation tissue was largely resolved in  
Wt mice (Fig. 1A, B).  In contrast, the area of tenascin-positive granulation tissue in day 3 and 7 
Rh-/- wounds was significantly smaller than in Wt wounds.  Day 14 wounds of Rh-/- mice were 
 6
still strongly tenascin-positive, although the areas of these regions were highly variable between 
Rh-/- mice (Fig. 1A, B).  Interestingly, the pattern of tenascin staining in day 14 Rh-/- wounds 
was abnormal as the staining was “patchy”, in contrast to day 14 Wt wounds (Fig. 1A).  An 
additional difference in Rh-/- wounds was the transient appearance of a thick layer of 
subcutaneous adipocytes in day 1-3 Rh-/- wounds (Fig. 2A and “unpublished data”). These 
results indicate that a prominent effect of Rhamm deficiency during wound repair is a miscuing 
of signals required for the temporal regulation of granulation tissue formation and resolution.    
Fibroplasia is a particularly prominent feature of granulation tissue in excisional skin 
wounds. The biological activities of fibroblasts and other mesenchymal cells, such as 
myofibroblasts, are key factors in the formation of early granulation tissue architecture (Reid et 
al., 2004).  Robust fibroplasia, as quantified by the density/unit area of granulation tissue 
fibroblasts, was apparent in day 3 Wt wounds and was increased by day 7 (Fig. 2A). 
Myofibroblasts, detected by smooth muscle actin staining, were also abundant in Wt wounds by 
day 7 (Fig. 2B).  Fibroplasia was observed in day3/7 Rh-/- granulation tissue but was blunted 
appreciably in comparison to Wt wounds (Fig. 2A) and there was a significant decrease in the 
number of myofibroblasts in day 7 Rh-/- wounds compared to Wt (Fig. 2B).  Furthermore, Rh-/- 
granulation tissue was confirmed to contain abundant adipocytes, particularly at the wound edge, 
as indicated by the presence of vacuolated cells (Fig. 2A, arrows) which stained strongly with the 
lipophylic dye, BODIPY493/503 (Gocze and Freeman, 1994)  ("unpublished data ").  Rh-/- cells 
explanted from normal skin (day 0) and from day 7 wounds expressed less smooth muscle actin 
and accumulated more lipid than explanted Wt cells (Fig. 2C).  Thus, deletion of Rhamm results 
in lower fibroblast density and aberrant differentiation in Rh-/- granulation tissue.  
A number of factors can affect fibroplasia as granulation tissue forms.  For example, a 
chronic inflammatory response at the wound site is required to initiate fibroplasia and functions 
to provide growth factors and cytokines that attract fibroblasts into the wound site.  These factors 
regulate fibroblast migration, survival and proliferation (O'Leary et al., 2002).  Rhamm regulates 
white cell trafficking in vivo and proliferation/ apoptosis in culture (Adamia et al., 2005; Turley 
et al., 2002).  Surprisingly, in vivo analysis revealed a significantly greater percentage of 
polymorphonuclear cells (cell/field) in Rh-/- day 3 and day 7 granulation tissue (65+6; 40+12) 
compared to Wt (42+8 and 8+1, respectively) suggesting that Rhamm loss results in prolonged 
acute inflammation within excisional wounds.  However, proliferation, as measured by the 
number of murine Ki-67-positive nuclei in granulation tissue, was not significantly different 
 7
from Wt, nor was the rate of apoptosis significantly different in Rh-/- vs. Wt wounds when 
measured by ApopTag staining ("unpublished data").  While these data do not rule out a role for 
fibroblast proliferation/apoptosis in the blunted fibroplasia observed in Rh-/- wounds, they 
suggest that these are not dominant factors.  
Rhamm expression is required to sustain ERK1,2 activation during granulation tissue formation 
in vivo and in fibroblasts responding to growth factors in culture.  
Fibroblast migration also contributes to fibroplasia and requires appropriate temporal 
regulation of signaling pathways such as ERK1,2, which provide cues for promoting and 
sustaining migration/invasion (Krueger et al., 2001). Furthermore, these MAP kinases have been 
implicated in fibroblast differentiation into adipocytes, the most prominent being ERK1 (Bost et 
al., 2005). Since we have shown that Rhamm associates with ERK1 in fibroblasts and that this 
association is required for PDGF-BB stimulated ERK1,2 activation (Zhang et al., 1998), we 
hypothesized  that the activity of these MAP kinases may be deficient in Rh-/- wound 
granulation tissue and contribute to aberrant fibroblast migration/differentiation (Hornberg et al., 
2005).   Wt granulation tissue fibroblasts exhibited strong staining for the active forms of these 
kinases, as assessed with anti-phospho-ERK1,2 antibodies, at day 3 after wounding (Fig. 3). At 
this time, levels of phospho-ERK1,2 were also similar for Rh-/- vs. Wt granulation tissue, when 
standardized against total ERK1,2 levels (Fig. 3, graph).  Staining intensity for phospho-ERK1,2 
in Wt granulation tissue fibroblasts increased 6-fold by day 7 and did not drop significantly until 
day 13, whereas staining intensity of phospho-ERK1,2 had prematurely decreased in Rh-/- 
granulation tissue by day 7 (Fig. 3). These changes in active ERK1,2 of Rh-/- vs. Wt granulation 
tissue fibroblasts were not due to decreases in total ERK1,2 protein levels since immunoblot 
analyses revealed  that Rh-/- fibroblasts expressed similar amounts of ERK1,2 protein compared 
to Wt fibroblasts in vivo ("unpublished data"). These results indicate that ERK1,2 activity in Rh-
/- granulation tissue fibroblasts is aberrant and may contribute to the miscuing of granulation 
tissue formation/resolution of Rh-/- excisional wounds.   
To determine whether the aberrant ERK1,2 activity observed in Rh-/- granulation tissue 
fibroblasts in vivo is a cell autonomous or micro-environmental defect, we quantified the 
response of isolated Rh-/- vs. RhFL (full length Rhamm)-rescued Rh-/- fibroblasts to serum (FCS) 
(Fig. 4). ELISA analysis of active (phospho)-ERK1,2 revealed that both RhFL-rescued and Rh-/- 
fibroblasts activated ERK1,2 in response to serum but activity declined more rapidly in Rh-/- 
fibroblasts (Fig. 4A).  ERK1 activity in response to serum also prematurely decreased as 
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assessed using Western blot analyses (Fig. 4B).  In contrast, RhFL-rescued fibroblasts sustained 
ERK1 activity for greater than 60 min, analogous to the Wt fibroblasts stimulated with PDGF-
BB (Fig. 4B, Suppl. Fig. IIIa).   
Confocal analysis showed that both RhFL-rescued and Rh-/- fibroblasts activate and target 
ERK1,2 to the cell nucleus (Fig. 4C).  However, activated ERK1,2 accumulated to a lesser extent 
and disappeared more rapidly from the nucleus of Rh-/- fibroblasts than the nucleus of the RhFL-
rescued counterparts (Fig. 4C, Suppl. Fig. IIIb).  Importantly, very little activated ERK1,2 
accumulated at the membrane of Rh-/- cell processes while these MAP kinases were clearly 
activated and targeted to cellular processes in RhFL-rescued fibroblasts or in Wt fibroblasts (Fig. 
4C and “unpublished data”).  These results suggest that Rhamm is required both for sustaining 
ERK1,2 activity in different subcellular compartments and for the appropriate temporal 
regulation of trafficking active ERK1,2, both of which could result in motility and differentiation 
defects (Hornberg et al., 2005).     
Rhamm expression is required for fibroblast migration and invasion in culture assays. 
To assess whether or not Rh-/- fibroblasts have an inherent migration defect, their 
motogenic behaviour was compared with RhFL-rescued fibroblasts using scratch wound and 3D 
collagen gel assays designed to mimic aspects of migration within the wound microenvironment 
(Reid et al., 2004).  Significantly fewer Rh-/- than RhFL-rescued fibroblasts migrated across 3mm 
scratch wounds in culture (Fig. 5A), as quantified both by the number of fibroblasts present in 
the wound gap and by time-lapse cinemicrography of fibroblasts migrating from the wound edge 
into the wound.  A similar difference in migration was also exhibited when comparing Rh-/- 
fibroblasts to litter-matched Wt fibroblasts (Suppl. Fig. IVa).  Vector analysis of time-lapse 
wound images revealed that Rh-/- fibroblasts were not restrained to a vertical orientation towards 
the wound gap, as was characteristic of the RhFL-rescued fibroblasts or Wt fibroblasts (Fig. 5A, 
Suppl. Fig. IVa). These results indicate that loss of Rhamm expression results in an inherent 
migration defect related to a reduced ability of fibroblasts to orient towards haptotactic cues.  
The invasive properties of Rh-/- vs. Wt fibroblasts were also compared using 3D collagen type I 
gels.  Gels were constructed with central plugs composed of collagen type I, PDGF-BB and HA, 
surrounded by fibroblasts enmeshed in the surrounding collagen gel (Fig. 5B).  Migration of 
primary Rh-/- dermal fibroblasts into the central collagen gel plug containing PDGF-BB and HA 
was reduced by almost 90% compared to that of litter-matched Wt fibroblasts (Fig. 5B).  A 
similar result was obtained with primary fibroblasts (Suppl. Fig. IVb) confirming that Rh-/- 
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fibroblasts exhibited intrinsic and severe defects in haptotaxis and invasion in vitro.  Cell surface 
Rhamm [also designated CD168 (Mason et al., 2002)] is important in this migration since anti-
Rhamm antibodies blocked the haptotaxis/invasion of Wt fibroblasts but not Rh-/- fibroblasts 
(Suppl. Fig. IV b).    
Efficient repair of excisional wounds also depends upon the speed of motility in response 
to motogens present in the microenvironment (Li et al., 2004; Ridley et al., 2003).  The velocity 
of migration stimulated by HA (Fig. 6A) or FCS (Suppl. Fig. Va,b) was assessed directly using 
time-lapse cinemicrography of cells cultured on 2D tissue culture surfaces.    All experiments 
measuring the effects of HA on motility rates were conducted using cells plated onto fibronectin-
coated culture surfaces, as described previously (Hall et al., 1996).  Since both higher molecular 
weight HA (avg. 300kDa) and HA oligosaccharides (avg. 10kDa) promote cell motility (Turley 
et al., 2002), a mixture of these HA sizes was used for the motility assays.  To render non-
transformed cells sensitive to HA, fibroblasts can be pre-treated with PMA, which is required to 
activate protein kinase C-dependent processes, permitting motogenic responses to HA (Hall et 
al., 2001).  The HA mixture significantly promoted random motility of Wt fibroblasts when 
PMA was present compared to PMA-treated cells alone (Fig. 6A), which is blocked by anti-
Rhamm antibodies (Fig. 6A).   In contrast, the HA formulation did not enhance Rh-/- fibroblast 
random motility; motility rates of these cells remained significantly lower than HA-stimulated 
Wt fibroblasts.  As expected, anti-Rhamm antibodies had no effect on the motility rates of the 
Rh-/- fibroblasts (Fig. 6A). The inability of Rh-/- fibroblasts to increase random motility in 
response to HA was not due to lack of expression of CD44, which was expressed at equal levels 
in both Rh-/- and Wt fibroblasts (Fig. 6B).  A similar result was observed when Rh-/- and Wt 
fibroblasts were stimulated with serum and motility of Wt fibroblasts was significantly inhibited 
by a Mek1 inhibitor, PD98059, or anti-Rhamm antibodies (Suppl. Fig. Va).  The motility of Rh-
/- fibroblasts was not affected by these inhibitors (Suppl. Fig. Va).  These results indicate that 
Rhamm expression is required for a motogenic response to HA and serum, and that serum-
induced motility is also dependent upon ERK1,2.  
Cell migration and invasion requires the rapid assembly/disassembly of the actin 
cytoskeleton.  Since intracellular Rhamm forms associate with the actin cytoskeleton (Turley et 
al., 2002), we compared the ability of Rh-/- fibroblasts with RhFL-rescued fibroblasts to 
disassemble phalloidin-positive actin stress fibers in response to PDGF-BB.  Unstimulated Rh-/- 
fibroblasts exhibited similar actin stress fibers to RhFL-rescued fibroblasts (Fig. 7). 
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Immunofluorescent brightness of these structures, which provides a measure of disassembly, was 
also similar (Fig. 7).  However, following exposure to PDGF-BB, Rh-/- fibroblasts exhibited a 
significantly reduced ability to disassemble actin fibers compared to Wt fibroblasts (Fig. 7).  The 
Mek1 inhibitor, PD98059, also significantly blocked actin disassembly in response to PDGF-BB 
Wt fibroblasts (Fig. 7).  These results indicate that reduced migration is linked to defective 
mechanisms of disassembly of the actin cytoskeleton and that Rhamm-regulated disassembly 
requires ERK1,2 activity.  
Expression of mutant active Mek1 rescues the migration defect of Rhamm-/- fibroblasts. 
Migratory behavior, including random motility, migration in scratch wound assays, 
invasion and cytoskeleton disassembly, have been shown previously to require ERK1,2 activity 
(Juliano et al., 2004; Reddy et al., 2003). Therefore, we asked whether these aberrant migratory 
properties of Rh-/- fibroblasts resulted directly from deficient ERK1,2 activity. Expression of 
mutant-active Mek1 restored the ability of Rh-/- fibroblasts to sustain activation of ERK1,2 in 
response to FCS (Fig. 8A, B) and this effect was not enhanced further by co-expression of RhFL 
(Fig. 8A).  As well, expression of active Mek1 in Rh-/- fibroblasts restored both their ability to 
migrate across wound gaps and to invade collagen at rates similar to that of RhFL-rescued 
fibroblasts (Fig. 9A, B).    Expression of mutant active Mek1 also re-established the ability of 
Rh-/- fibroblasts to disassemble actin stress fibers and to increase random motility in response to 
PDGF-BB (Fig. 7, Suppl. Fig. Vb), to levels similar to that of RhFL-rescued fibroblasts.  Co-
expression of RhFL and Mek1 did not further stimulate migration compared to RhFL or Mek1 
alone (Fig. 9A, Suppl. Fig. Vb).  These results suggest that Rhamm and Mek1 act on the same 
motogenic signaling pathway since Mek1 can compensate for Rhamm in restoring motile and 
invasive behavior.  Collectively, the results demonstrate that a major motogenic effect of Rhamm 
is to regulate activation of the Mek1/ERK1,2 complexes, since co-expression of RhFL and Mek1 
does not enhance ERK1,2 activity further. 
 
 
 
 
 
 
 
 11
DISCUSSION 
This study identifies Rhamm as a fibrogenic factor that is required for appropriate timing 
and spatial regulation of granulation tissue formation and resolution.  A major consequence of 
Rhamm loss on granulation tissue formation/resolution is reduced/delayed fibroplasia associated 
with sparse fibroblast density, enhanced neutrophil accumulation and aberrant mesenchymal 
differentiation as indicated by reduced myofibroblast conversion and increased adipocyte 
accumulation within wound granulation tissue.  Our studies suggest further that an underlying 
defect associated with these repair deficiencies in Rh-/- wounds is de-regulated ERK1,2 
activation that, in particular, impacts upon signaling pathways promoting fibroblast migration.  
This conclusion is supported by the demonstration that Rh-/- fibroblasts retain their inability to 
appropriately activate ERK1,2 in culture and result in migration defects, as measured by several 
locomotion assays.  These defects are rescued by expression of mutant active Mek1, an ERK1,2 
kinase activator.   
   We have previously reported that Rh-/- fibroblasts exhibit reduced proliferation in culture 
(Tolg et al., 2003).  However, our current data do not provide support for an essential role of 
Rhamm in mitotic spindle formation or cell cycle regulation during wound repair in dermal 
fibroblasts in vivo, as judged by the lack of detectable differences in proliferation or apoptotic 
indices within Rh-/- vs. litter-matched Wt wound sites. Nevertheless, the slightly disorganized 
migration of Rhamm-/- fibroblasts from scratch wound assays on tissue culture plastic is 
consistent with a possible centrosomal defect that could contribute to aberrant migration 
(Watanabe et al., 2005) and merits further experimentation.  A role for Rhamm in collagen 
contraction has also been controversial (Bagli et al., 1999; Travis et al., 2001).  Unexpectedly, 
however, our studies have revealed a role for Rhamm in recruitment/differentiation of 
myofibroblasts and contraction of the wound bed.  As is increasingly reported and recognized 
(Bissell et al., 2003), both of these results emphasize the importance of context and the 
microenvironment in regulating cell signaling.  Thus, data obtained in culture, especially on two-
dimensional (2D) substrata, need to be confirmed in vivo or at least in relevant 
microenvironments.   
  ERK1 and 2 are closely related MAP kinase isoforms that perform different physiological 
functions.  For example, ERK2 is required for normal embryogenesis (Yao et al., 2003), whereas 
ERK1 plays more subtle and specific roles in adult physiology including adipogenesis (Bost et 
al., 2005).  Both MAP kinases are activated by Mek1 or 2 and regulate signaling pathways that 
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control cell motility, invasion and cytoskeleton remodeling during migration in culture.  Our 
results show that these defects of Rh-/- fibroblasts result from an inability to sustain and 
maximally activate ERK1,2  following growth factor stimulation.  These results are consistent 
with our previous evidence that Rhamm is required for PDGF-BB stimulated ERK1,2 activity in 
mesenchymal stem cells and for promoting migration by regulating signaling through upstream 
activators of ERK1,2 including HA, Src, Ras and FAK (Hall et al., 1996; Hall et al., 1995; 
Turley et al., 2002).   
Loss of Rhamm results in an abnormal temporal regulation of the subcellular localization 
of ERK1,2 in response to certain fibrogenic factors. We show that appropriate activation and 
compartmentalization of active ERK1,2 is required for generating highly motile cells and for 
repairing large wound gaps.  ERK1,2 regulates motility by both transcriptional and post-
transcriptional mechanisms (Huang et al., 2004). Initiation and early phases of migration during 
wound repair do not appear to require transcription (Providence and Higgins, 2004). Rhamm 
may therefore affect the ability of ERK1,2 to regulate transcription of motility- and invasion-
related genes.  ERK1,2 kinases are activated in response to a wide variety of stimuli and 
phosphorylate multiple substrates that mediate such disparate cellular functions as proliferation, 
apoptosis and differentiation (Lewis et al., 2000).  The consequences of ERK1,2 signaling to 
these functions depends upon activation kinetics and subcellular compartmentalization (Colucci-
D'Amato et al., 2003; Hendriks et al., 2005; Hornberg et al., 2005).  These factors are determined 
by receptor dimerization, receptor internalization, “cross-talk” with other receptors, association 
of ERK1,2 with adaptor proteins, and activation of other kinases or phosphatases that modify 
ERK1,2 activity (Colucci-D'Amato et al., 2003; Hornberg et al., 2005). The mechanisms by 
which Rhamm controls the sustained ERK1,2 activation and compartmentalization are currently 
unknown, but intracellular Rhamm may act as an adaptor protein analogous to MP1 or IQGAP1 
(Kolch, 2005) while cell surface Rhamm forms may act as co-receptors for growth factors and 
their cognate receptors (Zhang et al., 1998) to separately regulate ERK activity.  
 Motogenic responses to PDGF-BB or FCS are reduced but are not ablated completely in 
the absence of Rhamm, suggesting that other factors can partially compensate for loss of 
Rhamm. However, our data show that Rhamm expression is essential for a motogenic response 
of fibroblasts to HA even when CD44, a major HA receptor, is present (Toole, 2004), implying 
that a principle function of Rhamm in vivo is as an HA receptor.  The molecular mechanisms by 
which polysaccharides in general, and HA in particular, regulate physiological processes such as 
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tissue repair are not yet well understood (Adamia et al., 2005; Toole, 2004). However, much like 
the closely related heparan sulfate, HA can impact signaling via receptors such as CD44 and 
Rhamm through their associations with growth factor receptors involved in repair such as TGF-
βR and PDGFR (Turley et al., 2002).   One way in which HA has been shown to affect signaling 
is by localizing growth factor receptors to specific cell surface membrane compartments.  For 
example, HA and CD44 promote localization of fibrogenic receptors such as TGF-βR into lipid-
rich rafts (Ito et al., 2004).  This type of compartmentalization impacts the rate of internalization 
and intracellular trafficking of receptor/signaling complexes to endosomes and lysosomes for 
inactivation vs. recycling back to the cell surface.  These parameters, in turn, have an effect on 
the kinetics of receptor activation including receptor-mediated activation of downstream 
effectors such as ERK1,2 (Hendriks et al., 2005).  CD44, furthermore, links growth factor 
receptors such as TGF-βR to the cortical cytoskeleton (Turley et al., 2002).  Like CD44, Rhamm 
has been shown to mediate signaling through TGF-β and PDGF-BB (Turley et al., 2002).  
Furthermore, the loss of Rhamm has similar effects on fibroblast migration and ERK1,2 
activation in culture as does loss of PDGFR (Gao et al., 2005).   How Rhamm directs signaling 
by HA and fibrogenic cytokines such as PDGF-BB remains to be determined. 
Rhamm does appear to be required as a mediator of HA/cytokine signaling. However, 
Rhamm does not perform all the functions attributed to HA.  For example, HA is essential for 
embryogenesis, whereas Rhamm is not (Tolg et al., 2003).  Therefore Rhamm, like CD44 (which 
also is not required for embryogenesis), must mediate only a subset of HA-regulated functions in 
vivo.  Most probably these include some HA-mediated functions that are distinct from CD44 but 
also some that are shared with CD44.   For example, Rhamm can compensate for HA-driven 
collagen-induced arthritis when CD44 is absent (Nedvetzki et al., 2004).  Furthermore, while 
loss of either CD44 or Rhamm have consequences on wound repair (Toole, 2004), we have 
shown in the present study that aberrant granulation tissue formation and resolution resulting 
from Rhamm loss cannot be compensated for by CD44 expression.  
To date, most of the reported effects of Rhamm in vivo are limited to mesenchymal and 
immune cells.  Loss of Rhamm appears to have no appreciable effect on the appearance of pre-
neoplastic polyps in the upper intestinal tract of APC-mutant transgenic mice, although it 
profoundly affects the initiation and invasion of mesenchymal tumors (Tolg et al., 2003).  
Furthermore, in CD44-/- mice, splenocytes utilize Rhamm for homing to damaged joints and 
Rhamm hyperexpression contributes to aggressive behavior of multiple myeloma subsets 
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assessed ex vivo (Adamia et al., 2005).  Here, we have noted that a dominant effect of Rhamm 
loss is on granulation tissue fibroblast and polymorphonuclear cell accumulation. Only minor 
and transient differences were observed in the keratinocyte layer of Rh-/- vs. Wt wounds 
("unpublished data"). Intriguingly, the loss of Rhamm expression affects wound repair in a 
manner that most closely resembles the loss of another mesenchymal protein, vimentin (Eckes et 
al., 2000), which is also predominantly expressed in fibroblasts and cells of hematopoietic 
lineage (Adamia et al., 2005; Eckes et al., 2000; Turley et al., 2002).  Like Rhamm, vimentin has 
been shown also to be essential for cell migration. Importantly, a prominent phenotype of 
vimentin knockouts is the aberrant formation/resolution of granulation tissue that results from 
impaired fibroblast migration.  Collectively, these results are consistent with the conclusion that 
Rhamm is a fibrogenic factor expressed predominantly in cells that do not necessarily form 
parenchymal units. These physiological functions may provide a basis for understanding and 
further dissecting the importance of Rhamm hyperexpression in the invasion and metastasis of 
malignant tumors, processes that are also regulated by vimentin. 
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MATERIALS AND METHODS 
Reagents  
Medical grade HA prepared from bacterial fermentation was the kind gift of Skye 
Pharma (London UK) and was free of detectable proteins, DNA or endotoxins (Filion and 
Phillips, 2001). The average molecular weight range and polydispersity of HA was 276.7kDa 
and 1.221kDa, respectively.  HA oligosaccharides (MWavg 10kDa) were a kind gift of Dr. F. 
Winnik (University of Montreal, QC) and were prepared by partial digestion with testicular 
hyaluronidase and purification by gel filtration.  Human plasma fibronectin (BRL) , Ki67 (pAb, 
DAKO), α- smooth muscle actin (pAb, Santa Cruz), tenascin (pAb, Chemicon) and vimentin 
(pAb, Santa Cruz) antibodies and Oregon Green phalloidin (Molecular Probes) were used 
according to the manufacturer’s instructions. Function blocking, affinity purified anti-Rhamm 
antibodies (Zymed) were confirmed to be specific by western blot and immunofluorescence 
assays of Rh-/- fibroblasts.  Anti-CD44 antibodies (mAb, KM114 and IM7, Pharmingen) were 
confirmed to be specific using western and immunofluorescence analyses of CD44-/- dermal 
fibroblasts.  Phospho-ERK1,2 antibodies (pAb, Cell Signaling Technology) were used for 
immunohistochemistry and immunofluorescence and phospho-ERK1,2 (mAb, Sigma) and pan-
ERK1 antibodies (pAb, Santa Cruz, ) were used for western blot analyses.  Secondary antibodies 
were anti-rabbit Alexa 555 (Molecular Probes), Texas-Red or FITC labeled goat anti-mouse/goat 
anti-rabbit (Jackson laboratories), HRP-goat anti-mouse (Biorad), HRP-goat anti-rabbit 
(Pharmingen), HRP-rabbit anti-goat (Santa Cruz). All antibodies were used according to 
manufacturer’s instructions. ABC staining system (Santa Cruz) was used for 
immunohistochemistry and ApoTag peroxidase in situ apoptosis detection kit (Chemicon) was 
used for quantification of apoptosis. FACE ERK1/2 ELISA kit (Active Motif) was used 
according to manufacturer's instructions to quantify ERK1/2 activation in response to FCS in Rh-
/-, RhFL-, Mek1- and Mek1/RhFL-rescued cell lines. Mounting medium for immunofluorescence 
contained DAPI (Vectashield) while Cytoseal 60 (Richard-Allan Scientific) was used for 
mounting of tissue sections.  The Mek1 inhibitors, PD98059 and U0126 (50µM and 10µM 
respectively, Biosciences), were used according to manufacturer’s instructions. BODIPY 
493/503 was purchased from Invitrogen and was used according to manufacturer's instructions. 
Rh-/- mice; mouse embryonic fibroblasts and dermal fibroblasts 
All animal experiments were performed in accordance with regulations of the animal use 
subcommittee at the University of Western Ontario, London, Ontario, Canada. The preparation 
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of Rh-/- mice and mouse embryonic fibroblasts (MEF), as well as genotyping of mice and 
fibroblasts, have been described (Tolg et al., 2003). CD44-/- mice have been described (Schmits 
et al , 1997). Dermal fibroblasts were isolated from explanted skin from newborn mice. For the 
isolation of cells from granulation tissue, wound punches were cut into small pieces and cultured 
with the dermal side facing down in complete cell culture medium (10% FCS, DMEM, 
antibiotic-antimycotic).  
RT-PCR analysis of Rhamm and CD44 mRNA  
Rhamm mRNA was amplified as previously described (Tolg et al., 2003) and PCR 
products were detected by Southern analysis using Rhamm exons 14-16 as a radioactive probe.  
CD44 mRNA was amplified as previously reported (Schmits et al., 1997).  Amplification of β-
actin mRNA was used as a loading control (Tolg et al., 2003).   
Western  blots  
Western analyses of CD44, phospho-ERK1,2 and total ERK1,2 proteins were performed 
as described (Schmits et al., 1997; Tolg et al., 2003; Zhang et al., 1998).  Densitometry was 
performed using Image Quant 5.1 software (Molecular Dynamics). 
Cell culture and transfection 
Cell culture medium and culture conditions were described previously (Tolg et al., 2003; 
Zhang et al., 1998).  PDGF-BB (25ng/ml), HA (500ng/ml-1mg/ml) or FCS (10%) were added to 
24hrs serum-starved, 50% sub-confluent fibroblasts on fibronectin (25µg/ml)-coated dishes (Hall 
et al., 1996; Zhang et al., 1998).  To obtain a response to HA, cells were pre-treated with 5nM 
PMA (Sigma) (Hall et al., 2001).  Immortalized Rh-/- cells were transfected with RhFL murine 
Rhamm and/or mutant active Mek1 (kind gift of N. Ahn, U. Colorado, Boulder) in the presence 
of Lipofectamine Plus (Invitrogen) as described previously (Zhang et al., 1998).  All 
transfectants were selected in G418 (1-5mg/ml for 2-3 weeks).  
Excisional wounds and histology 
Wt and Rh-/- mice (3-18 month old) were anaesthetized by Halothane inhalation.  Two 
full thickness wounds were placed on denuded back skin using a 4mm metal punch. Mice were 
housed in individual cages for the experimental period. Wounds were harvested at varying times 
using a 8mm metal punch from similar locations on the backs of mice of the same gender and 
age.  Harvested wounds were fixed overnight in 4% paraformaldehyde and paraffin embedded as 
described (Tolg et al., 2003).  Numbered serial sections were cut perpendicular to the wound 
edge starting at the wound center. The first and last sections were stained with Masson's 
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trichrome and non-stained sections were used for immunohistochemistry. To ensure that serial 
sections were cut starting at the wound center, wound samples were cut in half through the 
wound center prior to embedding   
In total, five experimental series were performed. In each experiment, wounds were 
harvested at four different time points (1, 3, 7, and 14 days after wounding). For each time point, 
four age and gender matched mice were used (two Rh-/- and two Wt mice).  In total, for each 
time point, ten Rh-/- and ten Wt mice were analyzed.    
Immunohistochemistry of tissue sections and immunofluorescence of cultured cells  
Tissue sections were stained for collagen (Masson's trichrome), α-smooth muscle actin, vimentin 
and tenascin following manufacturer's recommendations.  Staining was quantified after counter-
staining with Harris Hematoxylin (EM SCIENCE) and mounting in Cytoseal 60 (Tullberg-
Reinert and Jundt, 1999).  Immunofluorescence of phospho-ERK1,2 was done as previously 
published (Avizienyte et al., 2004). For the detection of droplets of neutral lipids, 
paraformaldehyde-fixed cells were stained with BODIPY 493/503 (25ug/ml) (Gocze and 
Freeman, 1994). Acton stress fibers were detected with Oregon-green phalloidin. 
In vitro wound and invasion assays  
Confluent cell monolayers on fibronectin coated dishes were serum starved overnight Scratch 
wounds (1 or 3 mm) were made using sized cell scrapers, then covered with medium containing 
10% FCS or 25ng/ml PDGF-BB for 24-48hrs.  Monolayers were fixed (3% paraformaldehyde), 
washed, stained with methylene blue (0.1% in methanol) then photographed using a Nikon 
inverted Eclipse TE 300 microscope.  Images were analyzed for cell number per unit area of 
wound gap using Simple PCI (Compix).  For 3D assays, collagen (Vitrogen100, Cohesion) or 
Matrigel (BD) gels were prepared according to manufacturers instructions. Plastic inserts were 
placed in the gel center. Fibroblasts were (5x105cells/ml) added to the outer gel ECM solution. 
After 24-48hrs, plastic inserts were removed and the cell free space was filled with collagen 
containing 25ng/ml PDGF-BB, 100µg/ml HA, and 25ng/ml fibronectin. Gels were fixed and 
analyzed 72hrs later for cell numbers/unit area..  
Time-lapse cinemicrography 
For experiments assessing the motogenic effects of HA and PDGF-BB, cells were plated 
onto fibronectin-coated tissue culture flasks at 50% sub-confluence overnight then serum-starved 
for 24hrs.  PDGF-BB or HA were added prior to filming as described (Hall et al., 2001; Zhang et 
al., 1998). For quantifying the effect of FCS, fibroblasts were plated at 50% sub-confluence 
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overnight onto tissue culture dishes that had been pre-coated with serum proteins.  FCS was 
added after a 24hr period of serum-starvation and cells were filmed as above.   
Image acquisition, image enhancement and image analysis  
Masson's trichrome and eosin/hematoxylin stained tissue sections as well as vimentin,  
tenascin and phospho-ERK1,2 stained tissue section images were taken with air objectives (4X, 
NA=0.16; 20X NA=0.7) using an Olympus AX70 Provis microscope equipped with a Cooke 
SensiCam color camera (CCD Imaging) and Image Pro Plus Version 4.5.1.2.9 software (Media 
Cybernetics, Inc.).   For quantification of pERK1,2 staining, images were saved as tiff files and 
quantification of histology staining was done using Photoshop 6.0 (Adobe). The area of blue 
Hematoxylin staining, representing number of cells, was quantified by selecting and counting 
blue pixels (select, color range, blue, Image, Histogram). After deletion of the selected blue 
pixels, the area stained by the peroxidase substrate DAB was identified by selecting shadows 
(select, color range, shadows) and quantified by measuring the number of pixels (Image, 
Histogram). The area stained with tenascin was quantified using Simple PCI imaging software 
(Compix). 
Images in Fig. 1A are composites of images taken with a 4x objective. The colors were 
enhanced using Photoshop 6.0 (Adobe, adjust, auto levels).   
Scratch wound images were taken with air objectives  (4x Nikon objective, air, NA=0.1, 
equipped with Hoffman modulation Contrast optics) using a Nikon Eclipse TE300 microscope 
equipped with a Hamamatsu digital camera (Hamamatsu) and Simple PCI imaging software 
(Compix). Images of the wounds were acquired using a Conica/Minolta Dimage Z3 digital 
camera equipped with 12x optical zoom. The wound area was quantified using Simple PCI 
imaging software (Compix).  Immunofluorescent images of actin fluorescence (10x Nikon 
objective, air, NA=0.25) were also acquired using the Nikon Eclipse TE300 microscope and 
quantified using Photoshop 6.0 as above.  Confocal images were taken using a 63X oil objective  
(Zeiss, NA=1.4) with a Zeiss 510 LSM Meta Confocal microscope using LSM 5 imaging 
software (Zeiss). Fluorescence intensity of images was measured using LSM 5 imaging software 
(Zeiss).  
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ABBREVIATIONS 
bFGF-2  Basic fibroblast growth factor-2 
2D  2-dimensional culture 
3D  3-dimensional culture 
ECM  Extracellular matrix 
ERK1,2 Extracellular regulated kinases 1,2 
FAK   Focal adhesion kinase 
HA  Hyaluronic Acid / Hyaluronan 
Matrigel Basement membrane matrix 
MEFs  Mouse embryonic fibroblasts 
Mek1   Mitogen activated kinase kinase 1 
MMPs  Matrix metalloproteinases 
MW  Molecular weight 
Mwavg  Average molecular weight 
PDGF-BB Platelet derived growth factor-BB 
PDGFR Platelet derived growth factor receptor 
PMNs  Polymorphonuclear cells 
Rhamm  Receptor for Hyaluronic Acid Mediated Motility 
RhFL  Full-length Rhamm 
Rh-/-  Rhamm -/- 
TE  Tris-EDTA 
TGF-β  Transforming growth factor-β 
TGF-βR Transforming growth factor-β receptor 
Wt  Wild-type 
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FIGURE LEGENDS 
 
 
Figure 1: Loss of Rhamm delays and alters the pattern of granulation tissue formation in 
skin wounds.  A.  Tenascin protein expression in wound sections:  Wound granulation tissue is 
abundant in day 7 Wt wounds as indicated by positive and homogenous staining for tenascin.  
Granulation tissue has largely resolved in Wt wounds by day 14 as indicated by restricted 
tenascin staining. The area of tenascin-positive Rh-/- granulation tissue is less in days 3 and 7 
than Wt and has become aberrantly "patchy" by day 14, indicating delayed and abnormal 
patterning of granulation tissue resolution.  Paraffin processed tissue sections were prepared 
perpendicular to the wound surface and cut at the wound center then stained for tenascin as a 
marker for granulation tissue.   B.  Areas of tenascin-positive granulation tissue:  The area of Wt 
granulation tissue is significantly greater than Rh-/- at both day 3 and 7 after wounding (p<0.01 
for both time points).  High standard errors of tenascin-positive areas of Rh-/- granulation tissue 
reflect aberrant resolution patterns.  Values represent the Mean and S.E.M. N= 4 tissue sections 
from 8 male mice for each genotype.  
 
Figure 2:  Loss of Rhamm reduces fibroblast density and increases granulation tissue cell 
heterogeneity.  A.  Fibroblast Density in granulation tissue:  The density of fibroblasts is 
significantly reduced in Rh-/- granulation tissue at both day 3 (p<0.0001) and 7 (p<0.001) after 
wounding. Arrows indicate the presence of vacuolated cells, which are adipocytes.  Fibroblast 
density is heterogeneous in Rh-/- granulation tissue (e.g. dotted circle is sparse; filled line circle 
is dense) but fibroblast density shown in graph was averaged per microscope field. Paraffin 
processed tissue sections were stained for vimentin.  Values in graphs represent the Mean and 
S.E.M., N=4 sections from 8 animals for each genotype.  B. Smooth muscle actin-positive 
fibroblasts in wounds: The number of wound myofibroblasts is significantly reduced in day 7 
Rh-/- wounds compared to Wt granulation tissue (p<0.0001). Paraffin processed tissue sections 
were stained for α−smooth muscle actin as described in Methods. Values in graphs represent the 
Mean and S.E.M., N=4 sections from 8 animals for each genotype.  C. Smooth muscle actin- and 
lipid-positive fibroblasts (adipocytes) in granulation tissue explants in culture: The numbers of 
smooth muscle actin-positive fibroblasts are significantly reduced and the numbers of lipid-
containing cells are significantly increased in Rh-/- granulation wound tissue when compared to 
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Wt (p<0.0001).  Cell outgrowths were stained with anti α−smooth muscle actin and 
BODIPY493/503 as described in Methods. In confocal images, red staining is smooth muscle 
actin and green staining is BODIPY493/503 taken up into lipid droplets within cells.  Laser 
settings were kept constant for Wt day 0 and Rh-/- day 0 images and for Wt day 7, Rh-/- day 7, 
IgG day 0 and acetone extracted day 0 images.  
     
Figure 3: Loss of Rhamm alters ERK1,2 activation in granulation tissue fibroblasts. Both 
Wt and Rh-/- granulation tissue fibroblasts are positive for activated (phospho)-ERK1,2 at day 3 
after wounding.  Staining for activated ERK1,2 significantly increases in Wt granulation tissue 
by day 7 (p<0.001), then drops by day 14.  In contrast, staining drops to near background in day 
7 Rh-/- wound granulation tissue (p<0.00001), and remains significantly lower than Wt at day 14 
(p<0.01). Paraffin sections were stained with anti-phospho-ERK1,2 antibodies. Staining was 
quantified using image analysis and averaged per unit area of granulation tissue as described in 
Methods. Values represent the Mean and S.E.M., N=15 images of 3 tissue sections for each 
genotype (5 mice each).  
    
Figure 4: Loss of Rhamm reduces serum activation of ERK1,2 in fibroblasts in culture.  A. 
ELISA analysis of phospho-ERK1,2:  RhFL-rescued fibroblasts sustain significantly higher levels 
of ERK1,2 activity at 30-60 min post serum stimulation than Rh-/- fibroblasts (p<0.05 for both 
time points). Phospho-ERK1,2 in serum starved RhFL-rescued  and Rh-/- fibroblasts exposed to 
serum were quantified as described in Methods. Values at 0 min were subtracted from values at 
30 and 60 min. Values represent the Mean and S.E.M., N=3 samples. B. Western blot analysis of 
phospsho-ERK1:  Quantification of ERK1 activity shows that RhFL-rescued fibroblasts sustain 
activity for 10-50 min post serum stimulation while activity drops in Rh-/- fibroblast 10 min after 
stimulation. Anti-phospho-ERK1,2 antibodies were used to detect active ERK1,2 in western 
blots. Phospho-ERK1 and total ERK1 were quantified by densitometry. Images and values for 
the graph are taken from one of 4 typical experiments.   C.  Confocal micrographs of phospho-
ERK1,2: Micrographs of  RhFL-rescued  and Rh-/- fibroblasts stained with anti-phospho-ERK1,2 
antibodies confirm the more rapid drop in activated ERK1,2 observed in Rh-/- compared to 
RhFL-rescued  fibroblasts, and show that targeting of phospho-ERK1,2 (red fluorescence) to cell 
processes and the nucleus (blue fluorescence) is also reduced in Rh-/- fibroblasts. Micrographs 
are taken from one of 4 similar experiments.  
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Figure 5:  Loss of Rhamm reduces fibroblast migration and invasion.  A.  Migration into 
scratch wounds: Transfection of immortalized Rh-/- fibroblasts with RhFL cDNA restores their 
ability to efficiently migrate into 3mm scratch wounds in response to PDGF-BB; significantly 
more RhFL-rescued fibroblasts migrate into the wound gap than Rh-/- fibroblasts (p<0.0001). 
Values represent the Mean and S.E.M., N=6 randomly chosen fields. Time-lapse analysis of 
wound edges shows that re-expression of RhFL permits Rh-/- fibroblasts to migrate longer 
distances over a 24 hr period.  Values represent the Mean and S.E.M. N=3 experiments. B.  
Invasion into collagen gels: Diagram shows the construction of a collagen gel invasion assay 
where HA and PDGF-BB is present only in the central plug. A significantly greater number of 
Wt dermal fibroblasts migrate into gel centers than do Rh-/- dermal fibroblasts (p<0.00001).  
Values represent the Mean and S.E.M., N=4 experiments.  
  
Figure 6: Loss of Rhamm ablates migration of fibroblasts in response to HA:  A.  Random 
motility in response to HA:  In contrast to Wt, Rh-/- fibroblasts do not increase random motility 
in response to HA. Further, Rhamm antibodies reduce motility of Wt but not Rh-/- fibroblasts in 
the presence of HA.  Fibroblasts were first exposed to PMA to generate responsiveness to HA. 
The values represent the Mean and S.E.M., N=30 cells and are the results of one of 4 similar 
experiments.   B.  CD44 protein expression:  Rh-/- fibroblasts express similar levels of CD44 
proteins as Wt,  assessed by western blot analysis. β-actin is used as a protein loading control.   
 
Figure 7:  Loss of Rhamm and inhibition of Mek1 activity reduce actin cytoskeleton 
disassembly.  Rh-/- fibroblasts form phalloidin-positive actin stress fibers similar in structure 
and immunofluorescent brightness (graph) to RhFL-rescued fibroblasts but do not disassemble 
these structures to the same extent as rescued fibroblasts in response to PDGF-BB.  The ability 
of RhFL-rescued fibroblasts to disassemble actin stress fibers in response to PDGF-BB requires 
ERK1,2 activation since the Mek1 inhibitor, PD98059, inhibits this process.  Conversely, 
expression of mutant active Mek1 in Rh-/- fibroblasts restores an ability to disassemble actin 
stress fibers in response to PDGF-BB.  Significant differences in fluorescence of actin are 
marked by asterisks (p<0.0001).  Values represent the Mean and S.E.M., N=30 
images/treatment.    
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Figure 8:  Mutant active Mek1 rescues aberrant ERK1,2 activity in Rhamm-/- fibroblasts.   
A. ELISA analysis of ERK1,2 activity:   Expression of mutant active Mek1 in Rh-/- fibroblasts 
restores ERK1,2 activation (p< 0.05 for 30 and 60 min) in response to serum stimulation and 
activity is not further increased by co-expression of RhFL and mutant active Mek1 Phospho-
ERK1,2 in serum starved Rh-/-, Mek1-rescued and Mek1/RhFL-rescued fibroblasts exposed to 
serum was quantified as described in Methods. Values at 0 min were subtracted from values at 
30 and 60 min. Values represent the Mean and S.E.M., N=3 samples. B.  Western blot analysis of 
ERK1 activity: Western blot analyses show that expression of mutant active Mek1 rescues the 
ability of Rh-/- fibroblasts to activate ERK1.  The graph is a typical result of 3 separate 
experiments.   
 
Figure 9:  Mutant active Mek1 rescues migration and invasion defects in Rhamm-/- 
fibroblasts.  A. Scratch wound migration assay:  Expression of mutant active Mek1 in Rh-/- 
fibroblasts restores their ability to migrate into a 3 mm wound gap in response to PDGF-BB to a 
similar extent as expression of full-length Rhamm. Co-expression of Mek1 and RhFL has no 
additive effect on migration. Asterisks indicate p<0.01.  Values represent the Mean and S.E.M., 
N=3 experiments.  B. Collagen gel invasion assay:  Expression of mutant active Mek1 in Rh-/- 
fibroblasts rescues the ability of Rh-/- fibroblasts to invade into collagen gel centers (see Figure 
5B) to a similar extent as expression of RhFL.  Asterisks indicate p<0.00001.  Values represent 
the Mean and S.E.M., N=3 experiments.    
  
Supplemental Figure I.  Rhamm expression is regulated during early phases of wound 
repair and loss of Rhamm reduces wound contraction. a. Rhamm mRNA expression in 
excisional wounds: Rhamm mRNA expression is transiently up-regulated following excisional 
skin injury. Rhamm mRNA was amplified by RT-PCR and PCR products were visualized by 
Southern analysis using a Rhamm-specific probe.  The band (arrow) represents the full-length 
Rhamm PCR product.  RT-PCR of β-actin mRNA was used as a loading control. b. Macroscopic 
quantification of wound contraction:  Analyses of excisional areas from photographs of wounds 
show that Wt wounds contract more rapidly than Rh-/- wounds with a significant difference 
observed at day 3 after wounding (p<0.05).  The circled area denotes forming granulation tissue, 
which is reduced in Rh-/- vs. Wt wounds.  c. Microscopic quantification of wound contraction.  
Analyses of tissue sections of wounds reveal a significant reduction in contraction at day 1 
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(p<0.0001), day 3 (p<0.05) and day 13 (p<0.001) in Rh-/- vs. Wt wounds.  Wound contraction 
was measured as the distance between the edges of each wound site using tissue sections cut at 
the center of the excisional wound.  Values represent the Mean and S.E.M. of 3 sections from 3 
wounds of each genotype. 
 
Supplemental Figure II. Loss of Rhamm expression results in aberrant dermal structure 
and thickness in both uninjured and repaired skin.    a. Dermis of uninjured skin: The dermis 
of uninjured Wt skin (day 0) is significantly thicker than uninjured Rh-/- skin (p<0.0001). 
Sections were stained with Masson’s Trichrome.  b. Dermis of resolved wounds: The dermis at 
both the center and edges of Wt wounds at day 21 are resolved in that histology is similar to 
uninjured skin.   Wt dermis is significantly thinner than Rh-/- wounds (p< 0.0001 and p<0.01).  
Rh-/- wounds have not fully resolved, as indicated by increased dermal thickness suggesting 
continuing fibroplasias as well as reduced dermal differentiation compared to Wt wounds (e.g. 
hair follicles have not formed shafts, subcutaneous lipid layer is not formed and muscle layer is 
not continuous at the underside of wounds).  Paraffin-processed tissue sections were stained with 
Mason’s trichrome to visualize dermal collagen (a, green stain) or hematoxylin/eosin to visualize 
cells (b).  The thickness of the dermal layer was measured as the distance between the 
keratinocyte layer and the subcutaneous fat layer. Solid arrowheads mark the still discernable 
wound site in Rh-/- skin.  Solid arrows mark undifferentiated hair follicles and open arrow heads 
indicate ongoing fibroplasia and incomplete muscle formation observed at the underside of Rh-/- 
wounds. Values represent the Mean and S.E.M. of 5 areas from 3 separate tissue sections for 
each experimental condition. 
 
Supplemental Figure III.  Rhamm loss reduces ERK1,2 activation in primary fibroblasts.  
a. Western blot analysis of ERK1 activation in response to PDGF-BB:  Loss of Rhamm results in 
a more rapid drop in ERK1 activation following exposure to PDGF-BB than in litter-matched Wt 
fibroblasts. ERK1 activity was quantified using western blot assays and anti-phospho-ERK1,2 
antibodies.  The western blot and graph values are one of three typical experiments. b. 
Quantification of confocal analysis of ERK1,2 activation in response to FCS: Loss of Rhamm 
reduces accumulation of activated ERK1,2 in the nuclear/perinuclear area (p<0.05) compared to 
Wt. Immunofluorescence of phospho-ERK1,2 in the nucleus and peri-nucleus was quantified at 
 29
30 min post-stimulation with FCS using image analysis as described in Methods.  Values 
represent the Mean and S.E.M., N=10 cells.  
 
Supplemental Figure IV. Loss of Rhamm reduces migration and invasion of primary 
fibroblasts.  a. Migration into Scratch wounds: Significantly more Wt fibroblasts migrate into 
wound gaps than Rh-/- fibroblasts (p<0.0001). Values represent the Mean and S.E.M., N=6 
randomly chosen areas. Time-lapse analysis of wound edges shows that Wt fibroblasts migrate 
longer distances than Rh-/- fibroblasts over a 24 hr period (p<0.0001).  Values represent the 
Mean and S.E.M., N=3 experiments. b. Invasion into collagen gels: A significantly greater 
number of Wt fibroblasts invade into the center of collagen gels than Rh-/- fibroblasts 
(p<0.00001). Furthermore, anti-Rhamm antibodies significantly block invasion of Wt fibroblasts 
(p<0.00001) but not Rh-/- fibroblasts.  Non-immune IgG was used as a control for the anti-
Rhamm antibody.  Values represent the Mean and S.E.M., N=4 experiments.   
 
Supplemental Figure V.  ERK1,2 activity is required for a motogenic response to PDGF-
BB and mutant active Mek1 rescues the motogenic defect of Rhamm-/- fibroblasts. a. 
Effects of Mek1 inhibition on random motility:  Primary Wt fibroblasts increase random motility 
in response to FCS to a significantly greater extent than litter-matched Rh-/- fibroblasts. Both a 
Mek1 inhibitor, PD98059, and anti-Rhamm antibodies significantly reduce motility of Wt (but 
not Rh-/- fibroblasts) in the presence of FCS.  Asterisks denote significance levels of p<0.0001. 
The values represent the Mean and S.E.M., N=30 cells and are the results of one of 4 similar 
experiments.  b.  Motility of Rh-/- fibroblasts expressing mutant active Mek1:  Random motility 
of Rh-/- fibroblasts is significantly increased by either expression of RhFL or mutant active Mek1 
(p<0.0001). Co-expression of RhFL and mutant active Mek1 does not further increase cell 
motility.  Values represent the Mean and S.E.M., N=30 cells/treatment.      
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Figure 1.  (Tolg et al.)  Loss of Rhamm delays and alters the pattern of granulation tissue formation  in skin wounds
Figure 2.  (Tolg et al.)  Loss of Rhamm reduces fibroblast density and  increases granulation tissue cell heterogeneity
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Figure 3.  (Tolg et al.) Loss of Rhamm alters ERK1,2 activation in granulation tissue fibroblasts
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Figure 4.  (Tolg et al.)  Loss of Rhamm reduces serum activation of ERK1,2 in  fibroblasts in culture
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Figure 5.  (Tolg et al.)  Loss of Rhamm reduces fibroblast migration and invasion
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Figure 6.  (Tolg et al.)  Loss of Rhamm ablates migration of fibroblasts in response to HA
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Figure 7.  (Tolg et al.)  Loss of Rhamm and inhibition of Mek1 activity reduce actin cytoskeleton disassembly
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Figure 8.  (Tolg et al.)  Mutant active Mek1 rescues aberrant ERK1,2 activity in Rhamm-/- fibroblasts
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Figure 9.  (Tolg et al.) Mutant active Mek1 rescues migration and invasion defects of Rh-/- fibroblasts
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Supplemental Figure I.  (Tolg et al.) Rhamm expression is regulated during early phases of wound repair and
loss of Rhamm reduces wound contraction.
Wt day 0 Rh-/- day 0
Wt day 3
Wt day 7
Rh-/- day 3
Rh-/- day 7
3 mm
b.  Macroscopic quantification of wound contraction 
a. Rhamm expression in excisional wounds
Wt Rh-/-
Rhamm
d1 d2 d3 d7 d3  d0
beta-Actin
*
day1
0
5
10
15
20
*
*
W
ou
nd
 s
iz
e 
(a
rb
itr
ar
y 
un
its
)
Wt Rh-/- Wt Rh-/- Wt Rh-/- Wt Rh-/-
day 3 day 7 day 14
Supplemental Figure II.  (Tolg et al.)  Loss of Rhamm expression results in aberrant dermal structure and thickness
in both uninjured and repaired skin. 
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Supplemental Figure III.  (Tolg et al.)  Rhamm loss reduces ERK1,2 activation in primary  fibroblasts
a.  Western blot analysis  of ERK1 activation  in response to PDGF-BB b. Quantification of confocal analysis of ERK1,2 activation in 
response to FCS
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Supplemental Figure IV.  (Tolg et al.) Loss of Rhamm reduces migration and invasion of Wt and Rh-/- primary fibroblasts 
a.  Migration into scratch wounds b.  Invasion into collagen gels
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Supplemental Figure V.  (Tolg et al.)  ERK1,2 activity is required for a motogenic response to PDGF-BB and mutant active 
Mek1 rescues the motogenic defect of Rh-/- fibroblasts.  
a. Effects of Mek1 inhibition on random motility b. Motility of Rh-/- fibroblasts expressing mutant active Mek1
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